This study was conducted to test the antimicrobial activity of Kiwi fruit (Actinidia chinensis) as an alternative antibacterial agent against gram positive microorganism such as Staphylococcus aureus that causes infections that colonize the skin and mucosal surface, and Streptococcus pyogenes which causes sore throat, pharyngitis, necrotizing fasciitis and Streptococcal toxic shock syndrome. The use of fruit extract was considered due to the emergence of multiple drug resistant bacteria due to multiple exposure and improper administration of antibiotics. The researchers of the study generally aim to evaluate the effectiveness of Actinidia chinensis fruit extract against Staphylococcus aureus and Streptococcus pyogenes which specifically aims to determine its minimum inhibitory concentration by using micro broth dilution method and to also determine if there is a significant difference between the percentage inhibition of the minimum inhibitory concentration of vancomycin and kiwi fruit extract against the two microorganisms. Results showed that kiwi fruit extract has its minimum inhibitory concentration at 3.125mg/ml with a percentage inhibition of 80.27% against S. aureus and, also has its minimum inhibitory concentration at 0.731mg/ml with a percentage inhibition of 79.60% against S. pyogenes. The researchers found out that kiwi fruit extract has no significant difference to vancomycin against S. aureus but is significantly different from vancomycin against S. pyogenes. Therefore, kiwi fruit extract was concluded to be potential alternative medicine in treating S. aureus related infections but has a lower antimicrobial activity compared to vancomycin in treating S. pyogenes related infections.